FDA Grants Accelerated Approval to Inovio's Voceryq for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Inovio's DNA-based immunotherapy, Voceryq, for adults with recurrent respiratory papillomatosis (RRP) to reduce surgical frequency. This approval is based on clinical trials showing complete response, with patients requiring no surgery for 12 months post-treatment. Continued approval hinges on verification of clinical benefit through a confirmatory study.